# Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

> **NCT01231542** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 27 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** GSK1349572
- **DRUG:** Rifampin
- **DRUG:** Rifabutin

## Key facts

- **NCT ID:** NCT01231542
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-06-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231542, "Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01231542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*